First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) Trading Up 0.3% - Time to Buy?

Key Points

• FBT shares rose 0.3% on Friday, trading as high as GBX 1,899.20 and last changing hands at that level, slightly above the prior close of GBX 1,893.40.
• Trading volume was light, with about 150 shares exchanged versus an average daily volume of 991, marking an 85% decline from normal activity.
• The ETF has a market capitalization of £779.08 million, with a 50-day moving average of GBX 1,842.87 and a 200-day moving average of GBX 1,879.44.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT - ) shares were up 0.3% on Friday . The stock traded as high as GBX 1,899.20 and last traded at GBX 1,899.20. Approximately 150 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 991 shares. The stock had previously closed at GBX 1,893.40.

First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Stock Up 0.3%

The company has a market capitalization of £779.08 million and a price-to-earnings ratio of -1,726.55. The company's 50 day simple moving average is GBX 1,842.87 and its two-hundred day simple moving average is GBX 1,879.44.

About First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation

Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content. The company operates under the brand name of Blackbird. The company was founded in 1998 and is based in London, the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.